Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem – here’s why
Polling shows that 1 in 8 Americans have tried GLP-1 drugs. zimmytws/iStock via Getty Images Plus The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars. For the […]
Why ‘starving cancer’ could be key to slowing disease growth, according to doctors
What we eat plays a major role in our health and well-being, especially in the development of chronic disease. On a recent episode of Dr. Mark Hyman’s podcast, “The Dr. Hyman Show,” the physician and Function Health co-founder spoke about how eating habits can change the course of illness. Podcast guest Dr. Jason Fung, a […]
Brain scientists are seeking weight-loss drugs without the nausea : Shots – Health News – NPR
Brain scientists are seeking weight-loss drugs without the nausea : Shots – Health News NPR Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide Nature Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds Reuters A case study on cravings and a GLP-1 statnews.com How to keep Ozempic/Wegovy weight loss without the nausea ScienceDaily
Body Positivity For Thee, Ozempic For Me: Slimmed Down Celebrities Ditch The Self-Love Narrative
Celebrities spent years singing “love yourself” from the stage and lecturing all of us about radical body acceptance. But then, a funny thing happened: weight loss drugs hit the scene. Now, some members of Hollywood have lost half their body weight and have been scrubbing the evidence from their feeds, rewriting the script about what […]
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
：，这一成果由礼来公司Irina Jouravskaya研究小组经过不懈努力而取得。2025年11月20日出版的《柳叶刀》发表了这项成果。背景:肥胖是一种慢性疾病，是2型糖尿病及其并发症的重要诱因。…
Opinion: Trump’s regressive deal on GLP-1s misses the mark for patients like me
The U.S. government is finally flexing its negotiating muscle to reduce GLP-1 prices and expand access to these medicines — for weight loss — in federal health programs. President Trump’s much-anticipated “deal” with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the […]
I lost 30kg on Ozempic and Wegovy. Everyone says the jabs are ageing but I look 10 years YOUNGER. Here’s how I did it
While headlines about ‘Ozempic face’ warn that the rapid weight loss associated with GLP-1 drugs can prematurely age people’s skin, Andrea says she’s experienced the opposite.
GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis
GLP-1s are the hottest drugs on the market. While doctors have prescribed these drugs to treat type-2 diabetes for decades, these treatments broke into the public consciousness when they started to be used for weight loss. U.S. approval of Novo Nordisk’s anti-obesity drug Wegovy and Eli Lilly’s Zepbound has fueled the meteoric growth of both […]
Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes
A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.
Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes
OBJECTIVE Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the association between incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is), and these outcomes. We examined the association between incretin medication use and risk of […]